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ABSTRACT
Introduction: Infectious complications 
significantly increase morbidity and mor-
tality after renal transplantation. The im-
munosuppression used is the main risk 
factor and relates directly to the incidence 
and severity of infectious events. Meth-
ods: This is a retrospective cohort study, 
which assessed the incidence of infections 
and their risk factors among 1,676 kidney 
transplant recipients during the first year 
of follow-up. Results: Infectious events 
were observed in 821 (49%) patients. 
The mean number of infectious episodes 
among patients with at least one episode 
was 2.3 (1 - 12). The most prevalent in-
fectious complications were as follows: 
urinary tract infection (31.3%); cytomeg-
alovirus infection (12%); surgical wound 
infection (10.3%); herpes virus infection 
(9.1%); pulmonary infection (5.2%); 
and bloodstream infection (4.3%). Cold 
ischemia time and the use of deceased 
donor grafts were important risk factors 
for infectious episodes. Conclusions: In-
fections are highly prevalent in the first 
year following transplantation. The main 
infectious complication was urinary tract 
infection.
Keywords: kidney transplantation, infec-
tion, cohort studies, logistic models.
[J Bras Nefrol 2010;32(1):75-82]©Elsevier Editora Ltda.
INTRODUCTION
Infectious complications significantly in-
crease morbidity and mortality after renal 
transplantation.1 Several risk factors re-
lated to infectious complications are pre-
sent after renal transplantation, mainly 
the need for permanent immunosuppres-
sion. Immunosuppression and its modu-
lation are directly related to the incidence 
and severity of infectious events, mainly 
in the initial phases of transplantation, 
when the risk for rejection is also higher.1-3 
Approximately 80% of all renal transplant 
recipients have an infectious complication 
in the first year following transplantation.4 
Other conditions influence less uniformly 
the risk for the occurrence of infections af-
ter transplantation and are largely depen-
dent on the socioeconomic and hygiene-
sanitary status of the population studied. 
Population studies have shown that the 
incidence, morbidity, mortality, spectrum, 
chronological distribution of infectious 
events and their risk factors have signifi-
cant differences in the different geographi-
cal regions of the world, and are modified 
over the years. On the other hand, advan-
ces in diagnosis and treatment, in addition 
to better professional qualification, have 
determined a progressive reduction in the 
prevalence of infectious episodes in recent 
years.1,4-6
This study was carried out aiming at 
establishing the incidence of infectious 
complications and their risk factors after 
renal transplantation performed at our ins-
titution, and at comparing them with the 
results obtained at other centers.
 
METHODS
This study assessed 1676 medical re-
cords of recipients of renal transplanta-
tions performed from January 1998 to 
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March 2004, at the Hospital do Rim e Hipertensão 
or at the Hospital São Paulo, both affiliated to the 
Universidade Federal de São Paulo (UNIFESP). The 
research project had been previously approved by 
the Committee on Ethics in Research of UNIFESP 
(Protocol 0666/2005).
 
PATIENTS
Patients of both sexes, older than 18 years, were stu-
died. The presence, number, and types of all infectious 
events observed in the first year following transplan-
tation were analyzed. The infectious events were iden-
tified through the observation of clinical signs and 
symptoms and also through complementary labo-
ratory assessment indicated by the assisting medical 
team. Urinary tract infection (UTI) was defined as the 
presence of dysuria and/or pollakiuria, accompanied 
by fever and positive urine culture. Cytomegalovirus 
infection (CMV) was defined as the presence of fever, 
abdominal pain, and myalgia, accompanied or not 
by anemia, leukopenia with or without lymphope-
nia, confirmed by positive antigenemia in circulating 
blood, or the histopathologic evidence of the cha-
racteristic cytomegalic inclusions in patients under-
going biopsy of the gastrointestinal tract mucosa or 
of pulmonary tissue. All patients receiving induction 
immunosuppression with monoclonal or polyclonal 
antibodies and those considered to be at high risk for 
primary CMV, because of being CMV-seronegative 
recipients of grafts originating from seropositive 
donors, received prophylactic treatment with ganci-
clovir at the dose of 10 mg/kg/day for 14 days. The 
presence of purulent secretion at the site of the trans-
plant surgical incision, accompanied or not by fever 
and positive culture of the secretion, was defined as 
surgical wound infection. The diagnosis of herpetic 
infection was based only on clinical criteria. Labial 
herpes simplex infection was defined as the presence 
of small vesicles or painful ulcers, of hyperemic ulcer 
floor, observed in the cutaneous-mucosal junction of 
one or both lips. Genital herpes infection was defined 
as the presence of extensive vesicular, vesico-pustu-
lar or vesico-ulcerated lesions in the genital region. 
Herpes zoster infection was defined as the presence of 
vesicular, vesico-pustular or vesico-ulcerated lesions, 
of hyperemic ulcer floor, in body regions delimited by 
specific dermatomes. Pulmonary infections were de-
fined in the presence of respiratory insufficiency of 
any severity, accompanied by fever and compatible 
radiologic exam, with or without positive culture of 
bronchial aspirate. Bloodstream infection was defined 
as the presence of fever with positive culture of peri-
pheral blood, with no other clinical manifestations.
 
STUDY DESIGN AND DATA COLLECTION
This is a retrospective cohort study that established 
the incidence of infectious episodes in renal trans-
planted patients in the first year following transplan-
tation. Patients were classified according to the infec-
tion location in the different body systems, and the 
related risk factors were identified. In addition, the 
patient and graft survivals by the end of the first year 
of transplantation were assessed.
The following variables were analyzed: recipient’s 
age and sex; dialysis time; HLA compatibility; type of 
donor; previous renal transplantation; occurrence of 
blood transfusions before transplantation; cold ische-
mia time for grafts of deceased donors; immunosup-
pression type; etiology of chronic kidney failure; se-
rology for CMV, hepatitis B, and hepatitis C prior to 
transplantation; and occurrence and type of the infec-
tious event observed after transplantation. The HLA 
compatibility with the grafts obtained from living do-
nors was defined as identical when the recipient had 
HLA A, B, and DR haplotypes compatible with those 
of the donor; as haploidentical when up to two of 
those haplotypes were compatible; and distinct when 
the donor shared none of those HLA haplotypes with 
the receptor.
 
STATISTICAL ANALYSIS
Data were presented by using absolute and per-
centage frequencies, means, standard deviations, and 
minimum and maximum values when appropriate. 
The chi-square test was used for comparing catego-
rical variables. The Student t test was used for com-
paring continuous variables. The Kaplan-Meier me-
thod was used for univariate analyses of the patient 
and graft survivals. The log-rank method was used 
for comparing the survivals of patients with and wi-
thout infectious episodes. Simple and multiple logistic 
regression analyses were performed to establish the 
contributions of the following variables to the risk of 
infectious episodes after transplantation: recipient’s 
age and sex; dialysis time; HLA compatibility; type 
of donor; previous renal transplantation; occurrence 
of blood transfusions prior to transplantation; cold 
ischemia time for the grafts from deceased donors; 
type of immunosuppression; etiology of chronic 
kidney failure; serology for CMV, hepatitis B, and 
hepatitis C prior to transplantation. Only the varia-
bles with a statistically significant association in the 
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simple logistic regression model were included in the 
multiple logistic regression model. A p value < 0.05 
was considered statistically significant. All statistical 
analyses were performed by using the SPPS program 
(version 12.0, SPSS Inc., Chicago, IL, USA, 2003).
 
RESULTS
PATIENTS
The demographic characteristics of the 1676 patients 
included in the study according to the presence of in-
fectious episodes are shown in Table 1. Patients with 
infectious episodes as compared with those with no 
infectious episodes were as follows: older (41.4 ± 
12.2 vs. 37.7 ± 10.4; p < 0.05); predominantly males 
(55.9% vs. 54.2%; p < 0.05); had a longer dialysis 
time (47.2 ± 47.2 months vs. 32.5 ± 36.7 months; 
p < 0.05); had less HLA compatibility with the do-
nor (identical, 12.5%; haploidentical, 31.0%; and 
distinct, 13.2% vs. identical, 28.8%; haploidentical, 
36.7%; and distinct, 15.3%; p < 0.05); received more 
grafts from deceased donors (41.1% vs. 17.5%; p < 
0.05); underwent more retransplantation (2.1% vs. 
1.7%; p < 0.05) and more blood transfusion prior 
to transplantation (51% vs. 49%; p < 0.05); used 
more calcineurin inhibitors (cyclosporin/tacrolimus, 
66.3/28.2% vs. 34.2%/27.8%; p < 0.005), azathio-
prine (62.1% vs. 71.3%; p < 0.05), methylpredni-
solone (29.2% vs. 19.1%; p < 0.05), and induction 
immunosuppression with monoclonal and polyclonal 
antibodies (9.0%/7.1% vs. 2.6%/1.4%; p < 0.05). No 
significant difference was observed regarding the cold 
ischemia time for grafts obtained from deceased do-
nors, the use of prednisone, and the etiology of chro-
nic kidney failure between the groups analyzed.
 
INCIDENCE OF INFECTIOUS EPISODES
The infectious episodes had an incidence of 49% (821 
patients), and were more frequent in the first months 
following transplantation. The number of infectious 
episodes was 1882, of which, 588 (31.3%) occurred 
in the first month after transplantation, 452 (24%) 
in the second month, 230 (12.2%) in the third mon-
th, and 612 (32.5%) after the third month (Figure 1). 
The mean number of infectious episodes among pa-
tients who had at least one infectious episode was 2.3 
episodes per patient, ranging from one to 12 during 
the follow-up period. The number of deaths during 
the follow-up period was 64 (7.9%) in the group with 
infection and 16 (1.9%) in the group without infec-
tion (p > 0.001).
 
TYPES AND ETIOLOGY OF THE INFECTIOUS COMPLICATIONS
The distribution of the 1882 infectious episodes accor-
ding to types is as follows: UTI, 588 (31.3%); CMV 
infections, 225 (12%); surgical wound infections, 194 
(10.3%); herpetic infections, 172 (9.1%); pulmona-
ry infections, 99 (5.2%); bloodstream infections, 81 
(4.3%); infections at other sites, 523 (27.8%).
 Of the 588 episodes of UTI, etiology was attribu-
ted to Escherichia coli in 217 (37%), to Enterobacter 
sp in 112 (19%), to Klebsiella pnemumoniae in 65 
(11%), to Pseudomonas aeruginosa in 35 (6%), and 
to other agents in 159 (27%). Of the 225 episodes 
of CMV infection, 178 (79%) had positive antigene-
mia only in peripheral blood samples, 37 (16%) also 
had cytomegalic inclusions in biopsy of the gastroin-
testinal tract, 8 (4%) had cytomegalic inclusions in 
pulmonary biopsy, and 2 (1%) had them in samples 
obtained at other sites. The 194 episodes of surgical 
wound infection were attributed to the following 
agents: coagulase-negative Staphylococcus, 47 (24%); 
Staphylococcus aureus, 23 (12%); Enterobacter sp, 23 
(12%); Enterococcus, 17 (9%); and others, 47 (24%). 
The 172 episodes of herpetic infections were attribu-
ted to the following agents: genital herpes simplex, 
43 (25%) patients; labial herpes simplex, 42 (24%); 
herpes zoster on the thoracic region, 48 (29%); and 
herpes zoster on other locations, 23 (13%). Varicella 
was the clinical presentation of 16 (9%) patients wi-
th episodes of herpetic infections. The 99 episodes 
of pulmonary infection included six (6%) infections 
by coagulase-negative Staphylococcus, two (2%) by 
Pseudomonas aeruginosa, two (2%) by Pneumocisti 
carinii, and 30 (30.3%) by others. The etiology of 59 
episodes of pulmonary infections (59.9%) has not be-
en established. The etiology of 81 episodes of bloo-
dstream infection was attributed to Escherichia coli, 
coagulase-negative Staphylococcus, Enterobacter sp, 
Acinetobacter baumannii, and Staphylococcus au-
reus in 15 (19%), 10 (12%), 8 (10%), 7 (9%), and 7 
Figure 1. Number of infectious episodes according to 
time elapsed after transplantation.
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Table 1 DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH AND WITHOUT INFECTIOUS EPISODES FOLLOWING RENAL    
 TRANSPLANTATION 
     With infection            No infection               p
Total of patients 821 (49%) 855 (51%) < 0.001
Age (years) 41.4 ± 12.2 37.7 ± 10.4 < 0.001
Sex      
 Male 459 (55.9%) 541 (63.3%) < 0.002
 Female 362 (44.1%) 314 (36.7%) < 0.002
Dialysis time (months) 47.2 ± 47.2 32.5 ± 36.7 < 0.001
HLA compatibility      
 Identical 103 (12.5%) 246 (28.8%) < 0.001
 Haploidentical 254 (31.0%) 314 (36.7%) < 0.001
 Distinct 109 (13.2%) 131 (15.3%) < 0.001
Deceased donor 338 (41.2%) 149 (17.5%) < 0.001
Retransplantation 17 (2.1%) 15 (1.7%) < 0.001
Blood transfusions prior 
to transplantation 611 (51%) 586 (49%) 0.008
CIT/DD (minutes) 1276 (± 488.6) 1217 (± 470.6) NS
Immunosuppression      
 Calcineurin inhibitors      
  Cyclosporin 545 (66.3%) 241 (28.2%) 0.016
  Tacrolimus 281 (34.2%) 238 (27.8%) 0.005
 Adjuvant drug      
  Azathioprine 510 (62.1%) 610 (71.3%) < 0.001
  MMF 301 (36.6%) 170 (19.9%) < 0.001
  Prednisone 815 (99.2%) 847 (99.1%) NS
  Methylprednisolone 240 (29.2%) 163 (19.1%) < 0.001
  Sirolimus 42 (5.1%) 81 (9.4%) 0.001
 Monoclonal and polyclonal antibodies      
  Anti-CD3 74 (9.0%) 22 (2.6%) < 0.001
  Antithymocyte globulin 59 (7.1%) 12 (1.4%) < 0.001
Etiology of CRF      
 SAH 164 (20.0%) 162 (19.0%) NS
 Diabetes 49 (5.9%) 38 (4.5%) NS
 GMN 155 (18.8%) 183 (21.4%) NS
 Polycystic kidneys 48 (5.8%) 35 (4.1%) NS
 Lupus 32 (3.9%) 24 (2.8%) NS
 Undetermined 317 (38.6%) 363 (42.4%) NS
 Others 56 (6.8%) 50 (5.8%) NS
HLA compatibility: identical - A, B, and DR HLA haplotypes of the donor compatible with those of the recipient; haploidentical - com-
patibility in up to two of those haplotypes; distinct - no compatibility among those haplotypes. CIT/DD = cold ischemia time/deceased 
donors; MMF = mycophenolate mofetil; SAH = systemic arterial hypertension; GMN = glomerulonephrites; NS = nonsignifi cant.
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(9%) of those episodes, respectively. Other infectious 
agents were responsible for the remaining 33 (41%) 
episodes. The distributions of the infectious episodes 
according to the different types identified and the 
etiological agents identified are shown in Figure 2.
 
SURVIVAL ANALYSES
The patient and graft survival curves, including all los-
ses, are shown in Figure 3. The patient’s survival rates 
6 and 12 months after transplantation were significan-
tly lower among patients with infectious episodes than 
among those with no infection: 94.3% and 92.3% vs. 
98.1% and 98.1%, respectively (p < 0.05). Comparing 
patients with and without infectious episodes, the 
graft survival analysis showed survival rates 6 and 12 
months after transplantation of 94.5% and 93.2% vs. 
97.6% and 97.5%, respectively (p < 0.05).
 
RISK FACTORS FOR INFECTION
Simple logistic regression analysis has identified the 
following variables as risk factors for infectious epi-
sodes: female sex (OR 1.32, CI 1.038 – 1.69); age 
(1.02, CI 1.01 – 1.03); compatibility with haploiden-
tical living donor (OR 1.93, CI 1.45 – 2.56) and dis-
tinct living donor (OR 1.98, CI 1.41 – 2.80); retrans-
plantation (OR 2.75, CI 1.26 – 5.99); transplantation 
from deceased donor (OR 5.41, CI 4.01 – 7.31); 
blood transfusion prior to transplantation (OR 1.34, 
CI 1.08 – 1.67); positive serology for hepatitis C prior 
to transplantation (OR 1.96, CI 1.42 – 2.71); dialysis 
time (OR 1.06, CI 1.04 – 1.08); cold ischemia time 
(30-minute increments) (OR 1.02, CI 1.02 – 1.03); use 
of cyclosporin (OR 0.77, CI 0.63 – 0.95), tacrolimus 
(OR 1.34, CI 1.09 – 1.66); azathioprine (OR 0.65, 
CI 0.53 – 0.80), mycophenolate mofetil (OR 2.33, CI 
1.87 – 2.90); methylprednisolone (OR 1.75, CI 1.39 
– 2.20); sirolimus (OR 0.51, CI 0.35 – 0.75); and mo-
noclonal antibodies (OR 3.75, CI 2.30 – 6.09) and 
polyclonal antibodies (OR 5.43, CI 2.90 – 10.19).
Multiple logistic regression analysis is shown in 
Table 2. The variables that remained as significant 
risk factors associated with infectious episodes in that 
analysis are as follows: female sex (OR 1.28, CI 1.04 
– 1.59); age (OR 1.02, CI 1.01 – 1.03); haploidentical 
HLA compatibility (OR 1.71, CI 1.27 – 2.32); trans-
plantation from deceased donor (OR 3.29, CI 2.37 
– 4.58); use of immunosuppression with mycopheno-
late mofetil (OR 1.46, CI 1.14 – 1.86); use of immu-
nosuppression with anti-CD3 induction therapy (OR 
2.38, CI 1.40 – 4.04); and use of immunosuppression 
with antithymocyte globulin induction therapy (OR 
2.90, CI 1.51 – 5.57).
Figure 2. Absolute frequencies of the infectious 
episodes identifi ed in the fi rst year after renal 
transplantation and percentage frequencies of the 
corresponding etiological agents identifi ed. UTI, 
urinary tract infection; CMV, cytomegalovirus; GIT, 
gastrointestinal tract. 
Figure 3. Patient (A) and graft (B) survival curves, including 
all losses, of renal transplant recipients with and without 
infectious episodes identifi ed in the fi rst year of follow-
up.
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DISCUSSION
This study assesses the incidence of infectious episodes 
among a significant number of renal transplant reci-
pients followed up at the same institution. The preva-
lence of infections in transplanted patients varies in 
the different regions and countries. Many factors can 
interact modifying the risk for infections, such as the 
immunosuppression profile used, the post-operative 
care, and the profile of epidemiological exposures to 
the different infectious-contagious diseases. In addi-
tion, the unfavorable socioeconomic profile contribu-
tes to increase the incidence of those complications 
in developing countries.1,5,7 Although the incidence of 
infectious episodes varies significantly in different stu-
dies, the incidence of infection is usually higher in the 
first months following transplantation and is directly 
related to the immunosuppression dose used. In the 
first months following renal transplantation, hospital 
infections predominate, mainly those located in the 
urinary tract and surgical wound. Between the second 
and sixth months, viral and fungal opportunistic in-
fections predominate. After the sixth month, commu-
nity infections prevail.1-5
 In our case series, the incidence of infectious epi-
sodes during the first year following transplantation 
was 49%. Comparatively, this result indicates that 
the incidence of infectious episodes in renal transplant 
recipients among us is equivalent to that observed in 
other countries of different regions in the world. In 
2006, Alangaden et al.8 studied 127 renal transplan-
ted patients at a North-American center and reported 
infectious complications in 51% of those recipients. 
Similarly, in 2007, Pourmand et al.9 reported a 54.2% 
frequency of infectious episodes in 172 patients follo-
wed up at an Iranian center.
Of all different conditions studied significantly 
associated with the risk of developing infectious epi-
sodes after renal transplantation, those related to the 
graft cold ischemia time and to immunological fac-
tors stand out. In the logistic regression analysis, the 
variable most significantly associated with that risk 
was the use of deceased donors (OR 3.29, CI 2.37 – 
4.58). Each 30-minute increment in the cold ischemia 
time of the graft obtained from a deceased donor al-
so showed a significant and independent association 
with the risk of developing infectious episodes (OR 
1.02, CI 1.02 – 1.03). Prolonged tissue ischemia is 
known to facilitate and amplify the exposure of class 
I and II MHC antigens of the transplanted organ to 
the recipient’s immune system, favoring immune re-
cognition and increasing the chances of triggering 
the rejection process.10 The use of additional doses of 
immunosuppression for treating those rejections also 
increases the chances of infectious episodes, and this 
may justify the association between that variable and 
the risk for developing infectious episodes. In accor-
dance with that supposition, the use of methylpred-
nisolone has also been significantly associated with 
a higher risk for developing infectious episodes (OR 
1.29, CI 1 – 1.68). The transplantation from a de-
ceased donor has also been observed to have 5.4 ti-
mes more chance to develop infection as compared 
with the transplantation from a living HLA-identical 
sibling donor. The significant association of that va-
riable with the risk for developing infection may be 
Table 2 RISK FACTORS FOR THE DEVELOPMENT OF INFECTION AFTER TRANSPLANTATION – MULTIPLE LOGISTIC   REGRESSION ANALYSIS
  Odds Ratio CI 95% p
Female sex  1.288 [1.043 - 1.592] 0.019
Age (years)  1.022 [1.013 - 1.032] < 0.001
HLA compatibility      
 Haploidentical 1.719 [1.271 - 2.324] < 0.001
 Distinct 1.442 [0.998 - 2.082] 0.051
Retransplantation 2.212 [0.987 - 4.956] 0.054
Deceased donor 3.299 [2.373 - 4.585] < 0.001
Immunosuppression      
 MMF 1.462 [1.143 - 1.869] 0.002
 Methylprednisolone 1.299 [1.003 - 1.681] 0.047
 Anti-CD3 2.380 [1.400 - 4.045] 0.001
 Antithymocyte 2.907 [1.515 - 5.579] 0.001
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justified by the longer cold ischemia time usually ob-
served when renal transplantation is performed with 
that type of donor, thus, increasing the incidences of 
graft function delay and acute rejection.2
The UTI frequency was 31.3% of all infectious 
episodes identified, and the most frequently found 
etiological agents were Escherichia coli (37%), 
Enterobacter sp (19%), and Klebsiella sp (11%). 
Urinary tract infection is the most common infection 
among renal transplanted patients, with prevalence 
ranging from 35% to 80%, being mainly observed in 
the first three months following transplantation.4 A 
prospective study carried out by Heilberg in Brazil in 
2003 showed a 63% prevalence of UTI in renal trans-
planted children, the most frequently found etiologi-
cal agent being Escherichia coli (57%).11 In Spain, a 
prospective analysis involving 159 recipients with a 
follow-up time of two years has shown a frequency of 
infections of 1.1 episode per patient, UTI accounting 
for 46.6% of the infectious episodes identified, and 
Escherichia coli being the most frequently found etio-
logical agent.12
Only 12% of the infectious episodes were attri-
buted to CMV. Cytomegalovirus infection is usually 
observed in 50% to 80% of the renal transplanted pa-
tients and usually occurs in the first six months follo-
wing transplantation.2 The serological conditions of 
donors and recipients regarding CMV are routinely 
assessed at the UNIFESP renal transplantation units, 
significantly contributing to the prevention and tre-
atment of CMV infections. A study carried out in 
France by Giral et al.13 in 2001 compared the inci-
dence of CMV disease in a group of 319 renal trans-
planted patients who used azathioprine with that 
observed in another group of 126 patients who used 
mycophenolate mofetil. Those authors reported a si-
milar result regarding the incidence of CMV in both 
groups studied (21.6% vs. 24.1%, respectively).13 It is 
worth emphasizing that all patients of that case series 
received gancyclovir for at least 14 days with doses 
corrected according to the renal function.
 Surgical wound infections corresponded to 10.3% 
of all infectious episodes analyzed. In 2006, Alangaden 
et al8 reported a 7% incidence of infectious episodes 
in the surgical wound in a cohort of 127 renal trans-
planted patients. This result is also similar to that ob-
tained in 2009 by a Spanish group reporting a 7.9% 
incidence of that same complication.12
 Herpes virus infections, comprising both herpes 
simplex infections and severe clinical findings of her-
pes zoster, corresponded to 9.1% of all infectious 
episodes identified. Recent studies have shown that 
the incidence of herpes zoster may reach 0.5%, 1.9%, 
5.6% and 11.2%, by the end of the sixth month, first 
year, second year, and forth year after renal trans-
plantation, respectively.14 A significant correlation 
between the type of immunosuppression used and 
variations in the incidence and severity of herpetic 
infections has also been shown in renal transplant re-
cipients. In 2008, Gaber et al.15 compared a group of 
224 renal transplanted patients using sirolimus and 
tacrolimus with another group of 224 patients using 
sirolimus and cyclosporin, both on corticosteroids for 
12 months. Those authors reported a higher inciden-
ce of herpes simplex infection among patients using 
sirolimus and tacrolimus as compared with that of 
the group using sirolimus and cyclosporin (4.5% and 
0.4%, respectively; p = 0.01).
Respiratory tract infections corresponded to 8.9% 
of all infectious episodes identified. The option for the 
prophylactic use of antibiotics may justify the diffe-
rences observed in the different studies regarding the 
incidence of respiratory tract infections, which has 
ranged from 6.3%8,9 to 2.2%16 at the end of the 
first year following transplantation.
It is worth emphasizing the significant reductions 
observed in both the patient and graft short-term sur-
vivals in recipients with infectious episodes, indepen-
dently from the type and site of the infectious episodes 
and agents identified. The UTI in renal transplant re-
cipients with urologic complications,17 seropositivity 
for hepatitis B virus,18 and herpes simplex infection19 
have not determined a significant reduction in long-
term survival. Nevertheless, the influence of infectious 
episodes on the results of renal transplantation has 
not been systematically analyzed in recent studies.
In conclusion, this study established the inciden-
ce of infectious episodes in the first year following 
transplantation at a single center. The most prevalent 
infectious complications after renal transplantation 
among us are UTI, CMV, and surgical wound infec-
tion. Infections after renal transplantation cause sig-
nificant morbidity and mortality, justifying measures 
directed at the identification of risk factors and early 
treatment. A prolonged cold ischemia time and renal 
transplants from deceased donors were important risk 
factors for infections following renal transplantation.
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